<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01292005</url>
  </required_header>
  <id_info>
    <org_study_id>08-006648</org_study_id>
    <nct_id>NCT01292005</nct_id>
  </id_info>
  <brief_title>Pentoxifylline Treatment of Acute Pancreatitis</brief_title>
  <official_title>Pentoxifylline Treatment in Acute Pancreatitis; A Double-Blind Placebo-Controlled Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects (good and bad) of giving a drug called
      pentoxifylline to patients with acute pancreatitis, to see if it can improve blood tests
      associated with inflammation (tissue damage). Pentoxifylline is approved by the US Food and
      Drug Administration (FDA) for treatment of circulation problems, but its use in this study is
      investigational, which means that the FDA has not approved it for the treatment of
      pancreatitis. However, the FDA has allowed the use of pentoxifylline in this research study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be put in one of two groups by chance (as in the flip of a coin). This is done
      so that neither you nor the investigator will know which group you are in.

      You will be put into either the treatment group or the control group.

        -  The treatment group will receive a drug called pentoxifylline

        -  The control group will receive a placebo (matching pill that has no medication in it)
           You will take the pills by mouth starting from the time of admission. You will receive a
           total of 9 doses over the first three days of your hospitalization (72 hours).

      When subject have standard patient care blood draws, additional blood will be taken to do the
      research tests. The additional blood tests will be done every day for up to 5 days, after the
      administration of study drug or till the time of discharge whichever occurs earlier. The
      additional tests will require about 2 teaspoons (10 ml) of blood per day; the maximum amount
      of extra blood taken would be less than 3 tablespoons (40.0 ml). Information from your
      medical record will be gathered while you are hospitalized and after your discharge. The
      study will continue to gather clinical follow up information up to four months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in C-Reactive Protein (CRP)</measure>
    <time_frame>baseline, Day 1, Day 3</time_frame>
    <description>C-reactive protein is produced by the liver. The level of CRP rises when there is inflammation throughout the body. The normal value range for CRP = 1-10 mg/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Tumor Necrosis Factor (TNF)-Alpha</measure>
    <time_frame>baseline, Day 1, Day 3</time_frame>
    <description>Normal value range for TNF alpha = 0 - 22 pg/ml.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Interleukin (IL) IL-6</measure>
    <time_frame>baseline, Day 1, Day 3</time_frame>
    <description>Normal value range for IL-6 = 0 - 5 pg/ml.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Interleukin (IL) IL-8</measure>
    <time_frame>baseline, Day 1, Day 3</time_frame>
    <description>Normal value range for IL-8 = 0 - 5 pg/ml.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number Of Subjects With New Onset Organ Failure During Hospitalization</measure>
    <time_frame>1 week or until dismissal date whichever occurs earlier.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number Of Subjects With New Onset Pancreatic Necrosis During Hospitalization</measure>
    <time_frame>1 week or until dismissal date whichever occurs earlier</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Lengthy Hospital Stays</measure>
    <time_frame>30 days or until dismissal date, whichever occurs earlier</time_frame>
    <description>&quot;Lengthy&quot; was defined as either greater than 4 days or greater than 10 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>30 days or until dismissal date, whichever occurs earlier</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Intensive Care Unit (ICU) Stay</measure>
    <time_frame>30 days or until dismissal date, whichever occurs earlier</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Needed an Intensive Care Unit Stay</measure>
    <time_frame>30 days, or until dismissal, whichever came first</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Acute Pancreatitis</condition>
  <arm_group>
    <arm_group_label>Pentoxifylline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentoxifylline</intervention_name>
    <description>400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
    <arm_group_label>Pentoxifylline</arm_group_label>
    <other_name>Trental</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Predicted Severe Acute Pancreatitis

          2. Enrollment within 72 hours of diagnosis

          3. Ability to give informed consent

          4. Age &gt;17 years

        Exclusion Criteria:

          1. Moderate or severe congestive heart failure

          2. History of seizure disorder or demyelinating disease

          3. Nursing mothers

          4. Pregnancy

          5. History of prior tuberculosis or risk factors for tuberculosis

          6. Evidence of immunosuppression (malignancy, chronic renal failure, chemotherapy within
             60 days, ongoing steroid treatment*, and HIV)- (*the exception of prednisone use will
             be allowed to participate).

          7. Evidence of chronic pancreatitis from history and examination (however, &quot;acute on
             chronic pancreatitis&quot; diagnosis is allowed)

          8. Evidence of active or pending hemorrhage.

          9. Paralytic ileus with vomiting
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Santhi S Vege, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2010</study_first_submitted>
  <study_first_submitted_qc>February 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2011</study_first_posted>
  <results_first_submitted>September 23, 2013</results_first_submitted>
  <results_first_submitted_qc>October 23, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 13, 2013</results_first_posted>
  <last_update_submitted>September 14, 2016</last_update_submitted>
  <last_update_submitted_qc>September 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Santhi Swaroop Vege, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>pancreatitis</keyword>
  <keyword>pancreatic necrosis</keyword>
  <keyword>severe acute pancreatitis (SAP)</keyword>
  <keyword>Alcoholic pancreatitis</keyword>
  <keyword>gallstone pancreatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pentoxifylline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled from the Mayo Clinic in Rochester, Minnesota between 2009 and 2012.</recruitment_details>
      <pre_assignment_details>30 subjects signed informed consent; two subjects were excluded after consent because they were found to be not eligible.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pentoxifylline</title>
          <description>Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pentoxifylline</title>
          <description>Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69" lower_limit="34" upper_limit="87"/>
                    <measurement group_id="B2" value="58" lower_limit="24" upper_limit="82"/>
                    <measurement group_id="B3" value="64" lower_limit="24" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.2" lower_limit="20.6" upper_limit="42.9"/>
                    <measurement group_id="B2" value="32.5" lower_limit="16.7" upper_limit="50.1"/>
                    <measurement group_id="B3" value="30.3" lower_limit="16.7" upper_limit="50.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in C-Reactive Protein (CRP)</title>
        <description>C-reactive protein is produced by the liver. The level of CRP rises when there is inflammation throughout the body. The normal value range for CRP = 1-10 mg/L.</description>
        <time_frame>baseline, Day 1, Day 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pentoxifylline</title>
            <description>Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in C-Reactive Protein (CRP)</title>
          <description>C-reactive protein is produced by the liver. The level of CRP rises when there is inflammation throughout the body. The normal value range for CRP = 1-10 mg/L.</description>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline to Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.4" lower_limit="-37.1" upper_limit="207.3"/>
                    <measurement group_id="O2" value="60.6" lower_limit="-71" upper_limit="283.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62" lower_limit="-157.4" upper_limit="255.3"/>
                    <measurement group_id="O2" value="154" lower_limit="-170" upper_limit="193.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Day 0 to Day 1. p&lt;0.05 was considered statistically significant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.62</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Day 0 to Day 3. p&lt;0.05 was considered statistically significant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Tumor Necrosis Factor (TNF)-Alpha</title>
        <description>Normal value range for TNF alpha = 0 - 22 pg/ml.</description>
        <time_frame>baseline, Day 1, Day 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pentoxifylline</title>
            <description>Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Tumor Necrosis Factor (TNF)-Alpha</title>
          <description>Normal value range for TNF alpha = 0 - 22 pg/ml.</description>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline to Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-1.2" upper_limit="0.52"/>
                    <measurement group_id="O2" value="-0.05" lower_limit="-0.9" upper_limit="49.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="-1.0" upper_limit="0.5"/>
                    <measurement group_id="O2" value="-0.3" lower_limit="-3.5" upper_limit="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Day 0 to Day 1. p&lt;0.05 was considered statistically significant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.72</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Day 0 to Day 3. p&lt;0.05 was considered statistically significant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.50</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Interleukin (IL) IL-6</title>
        <description>Normal value range for IL-6 = 0 - 5 pg/ml.</description>
        <time_frame>baseline, Day 1, Day 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pentoxifylline</title>
            <description>Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interleukin (IL) IL-6</title>
          <description>Normal value range for IL-6 = 0 - 5 pg/ml.</description>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline to Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="-37" upper_limit="25"/>
                    <measurement group_id="O2" value="0.7" lower_limit="-62" upper_limit="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.6" lower_limit="-61" upper_limit="15.6"/>
                    <measurement group_id="O2" value="-2.9" lower_limit="-213" upper_limit="65.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Day 0 to Day 1. p&lt;0.05 was considered statistically significant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.58</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Day 0 to Day 3. p&lt;0.05 was considered statistically significant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.80</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Interleukin (IL) IL-8</title>
        <description>Normal value range for IL-8 = 0 - 5 pg/ml.</description>
        <time_frame>baseline, Day 1, Day 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pentoxifylline</title>
            <description>Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Interleukin (IL) IL-8</title>
          <description>Normal value range for IL-8 = 0 - 5 pg/ml.</description>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline to Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" lower_limit="-7.2" upper_limit="30.8"/>
                    <measurement group_id="O2" value="-1.7" lower_limit="-38.2" upper_limit="49.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" lower_limit="-10.3" upper_limit="5.4"/>
                    <measurement group_id="O2" value="-1.9" lower_limit="-43.6" upper_limit="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Day 0 to Day 1. p&lt;0.05 was considered statistically significant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.90</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Day 0 to Day 3. p&lt;0.05 was considered statistically significant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.56</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number Of Subjects With New Onset Organ Failure During Hospitalization</title>
        <time_frame>1 week or until dismissal date whichever occurs earlier.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pentoxifylline</title>
            <description>Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Number Of Subjects With New Onset Organ Failure During Hospitalization</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>p&lt;0.05 was considered statistically significant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.09</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number Of Subjects With New Onset Pancreatic Necrosis During Hospitalization</title>
        <time_frame>1 week or until dismissal date whichever occurs earlier</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pentoxifylline</title>
            <description>Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Number Of Subjects With New Onset Pancreatic Necrosis During Hospitalization</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>p&lt;0.05 was considered statistically significant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.22</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Lengthy Hospital Stays</title>
        <description>&quot;Lengthy&quot; was defined as either greater than 4 days or greater than 10 days.</description>
        <time_frame>30 days or until dismissal date, whichever occurs earlier</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pentoxifylline</title>
            <description>Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Lengthy Hospital Stays</title>
          <description>&quot;Lengthy&quot; was defined as either greater than 4 days or greater than 10 days.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Length of hospitalization &gt;4 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Length of hospitalization &gt;10 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between arms for length of hospitalization &gt; 4 days. P &lt; 0.05 was considered statistically significant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison was for length of hospitalization &gt;10 days. P &lt; 0.05 was considered statistically significant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Hospital Stay</title>
        <time_frame>30 days or until dismissal date, whichever occurs earlier</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pentoxifylline</title>
            <description>Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Hospital Stay</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O2" value="5" lower_limit="1" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P &lt; 0.05 was considered statistically significant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Intensive Care Unit (ICU) Stay</title>
        <time_frame>30 days or until dismissal date, whichever occurs earlier</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pentoxifylline</title>
            <description>Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Intensive Care Unit (ICU) Stay</title>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P &lt; 0.05 was considered statistically significant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Needed an Intensive Care Unit Stay</title>
        <time_frame>30 days, or until dismissal, whichever came first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pentoxifylline</title>
            <description>Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Needed an Intensive Care Unit Stay</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P &lt; 0.05 was considered statistically significant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pentoxifylline</title>
          <description>Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Santhi Swaroop Vege</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-284-2175</phone>
      <email>vege.santhi@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

